Andrew Hill Investment Advisors, Inc. on Eli Lilly and Company
Thesis
Eli Lilly is benefiting from strong demand for its diabetes and weight-loss therapies, which has materially changed its growth profile and generated substantial cash flow. The fund believes Lilly can reinvest that cash into research, development and strategic acquisitions to create a self-reinforcing innovation cycle. Its pipeline extends across oncology, neuroscience, immunology and emerging mental health treatments. The core thesis is that current GLP-1 leadership can fund future medical breakthroughs and sustain long-term growth.
“the company’s ability to convert today’s GLP-1 leadership into tomorrow’s medical breakthroughs makes it a compelling long-term investment.”